Results 201 to 210 of about 108,435 (311)

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab.

Oncology
Sheu M, Molina Garcia S, Patel M, Mushtaq A, Rust T, Anns Asif M, Anwer F, Majeed A.   +7 more
europepmc   +1 more source

IL-10 and IL-2R as combined predictors of intravenous immunoglobulin resistance in Kawasaki disease: a retrospective cohort study. [PDF]

Front Immunol
Wang HY, Chen S, Zhang C, Huang JH.
europepmc   +1 more source

Intravenous immunoglobulin therapy in rheumatic diseases

, 2011
Jagadeesh Bayry, Vir Singh Negi, Srini V. Kaveri   +2 more
openalex   +2 more sources

Sevoflurane‐induced periostitis

Arthritis &Rheumatology, Accepted Article.
Christian Beyer, Bernhard Manger, Marion Ganslmayer, Richard Strauß   +3 more
wiley   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Clinical Pharmacology &Therapeutics, EarlyView.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu, Farina Hellmann, Xiaowei Zang, Nele Plock, Keyur Parmar, Radha A. Railkar, S. Y. Amy Cheung, Brian M. Maas, Ferdous Gheyas   +8 more
wiley   +1 more source

Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan. [PDF]

Jpn J Ophthalmol
Takahashi Y, Kezuka T, Shikishima K, Yamagami A, Chuman H, Nakamura M, Ueki S, Kimura A, Hashimoto M, Tatsui S, Shoji N, Ishikawa H, Collaborative Research Group: Investigators.   +12 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. [PDF]

Rheumatology (Oxford)
Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Clodi E, Levine T, Aggarwal R.   +11 more
europepmc   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source